Case 1: Man Aged 55 Years With Stage IIIB Melanoma Developing Immunotherapy-Induced Diabetes

This is a video synopsis/summary of an OncLive Insights^® involving Afreen Shariff, MD, MBBS; Javid Moslehi, MD; and Nikhil Khushalani, MD.

This segment presents a case of immunotherapy-related type 1 diabetes mellitus (T1DM) in a 55-year-old man with stage IIIB wild-type melanoma on adjuvant nivolumab after surgery. After his third infusion, he developed hyperglycemia, elevated hemoglobin A1C level, T1DM antibodies positivity, low C-peptide level, and other symptoms meeting criteria for nivolumab-induced diabetic ketoacidosis.

When asked whether he has seen cases like this, Khushalani confirms that it is a known, though rare, immune-related adverse event that can occur with anti–PD-1 monotherapy or combination ipilimumab/nivolumab treatment.

Video synopsis is AI generated and reviewed by OncLive^® editorial staff.